资讯

FDA Suspends Muscular Dystrophy Drug After 3 Patient Deaths
The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...
pharmaphorum3 小时
Sarepta resists as FDA seeks pause on Elevidys use
Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...
Axios on MSN2 小时
Drugmaker refuses FDA request to pull gene therapy
An unusual public feud between the Food and Drug Administration and a maker of gene therapies for rare diseases could test ...
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys
The ground shook for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) last week as the U.S. Food and Drug Administration (FDA), ...
BioSpace35 分钟
Sarepta Stands Ground Against HHS Request to Stop Elevidys Shipments
In light of recent patient deaths, the FDA has also revoked its platform designation for Sarepta’s AAVrh74 technology. The ...
Hoodline22 小时
Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA ...
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
Sarepta stock extends decline as company declines FDA call to withdraw drug
Sarepta stock (SRPT) declined 5% in premarket trade, after falling 36% on Friday, when it disclosed a patient death due to liver failure.
These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More
Stock futures were rising Monday ahead of a week filled with earnings reports, including quarterly updates from Tesla and Alphabet, and as Wall Street monitored the latest trade developments.These ...
pharmaphorum1 小时
Roche's COPD candidate fails a phase 3 readout
"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...